文献速递免疫规划卫生政策与健康促进

美国呼吸道合胞病毒预防产品效果监测框架

A framework for monitoring RSV prevention product effectiveness in the United States.
PubMed 文献 · Vaccine · 2025-01-03

2023年美国疾病控制与预防中心(CDC)推荐了首批用于婴儿和老年人预防严重呼吸道合胞病毒(RSV)疾病的免疫产品。CDC与联邦、公共卫生及学术伙伴合作,通过高质量、良好对照的观察性研究评估RSV疫苗和尼塞韦单抗(nirsevimab)的真实世界效果,以支持免疫产品政策决策。

要点

  • 2023年CDC推荐首批RSV免疫产品用于婴儿和老年人。
  • CDC正通过观察性研究评估RSV疫苗和尼塞韦单抗的真实世界效果。
  • 监测框架旨在为RSV预防控制的免疫政策提供及时稳健证据。

核心结论

  • CDC的RSV免疫效果项目旨在通过观察性研究生成及时稳健证据,以支持免疫产品政策决策及RSV预防控制措施。

研究设计与样本

  • CDC与联邦、公共卫生及学术伙伴合作,利用多种平台开展高质量、良好对照的观察性研究评估RSV免疫产品效果。

主要发现

  • CDC正在对美国推荐的RSV免疫产品进行真实世界效果评估。
  • 针对RSV疫苗和尼塞韦单抗(nirsevimab)应用相似的评估框架来估计产品效果。

临床怎么用

  • CDC通过观察性研究评估RSV免疫产品效果,为免疫产品政策决策提供证据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During 2023, the Centers for Disease Control and Prevention (CDC) recommended the first respiratory syncytial virus (RSV) immunizations intended for widespread use in the United States to prevent severe RSV illness in infants and older adults. CDC, in collaboration with federal, public health, and academic partners, is conducting evaluations of real-world effectiveness of recommended RSV immunization products in the United States. Similar frameworks for evaluation are being applied to RSV vaccines and nirsevimab, a long-acting preventative monoclonal antibody, to estimate product effectiveness. The overall goal of CDC's RSV immunization effectiveness program is to generate timely and robust evidence through observational studies to inform immunization product policy decisions and other measures related to RSV prevention and control. CDC is evaluating effectiveness through high-quality, well-controlled observational studies leveraging a variety of platforms that provide robust data to inform policy decisions.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Roper LE, Link-Gelles R, Surie D, et al. A framework for monitoring RSV prevention product effectiveness in the United States. Vaccine. 2025. PMID: 39755055. doi:10.1016/j.vaccine.2024.126633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。